'Twincretin' Tirzepatide Gets FDA Approval for Type 2 Diabet
FDA's approval of tirzepatide, the first approved agent that works as a dual agonist for the two principal human incretins. Its agonist properties for both the glucagon-like peptide-1 (GLP-1) receptor, as well as the glucose-dependent insulinotropic polypeptide (GIP). Several agents are already approved for US use from the class with single-agonist activity on the GLP-1 receptor, including semaglutide. The pivotal trials included head-to-head comparisons between tirzepatide and a 1.0-mg/week dose of semaglutide, as well as comparisons with each of two long-acting insulin analogs, insulin glargine (Lantus) and insulin degludec (Tresiba).

The FDA's approved label includes all three dosages of tirzepatide that underwent testing in the pivotal trials: 5 mg, 10 mg, and 15 mg, each delivered by subcutaneous injection once a week. Also approved was the 2.5 mg/week dose used when starting a patient on the agent. Gradual up-titration appears to minimize possible gastrointestinal adverse effects during initial tirzepatide use. The analysis reports that tirzepatide had a better impact on patient quality of life compared with 1.0 mg/week semaglutide for treating patients with type 2 diabetes.

Source: https://www.medscape.com/viewarticle/974013#vp_1